Advaxis (ADXS) 10-Q 11 Jun 20 2020 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Apr. 30, 2020	Jun. 11, 2020
Document And Entity Information
Entity Registrant Name	Advaxis, Inc.
Entity Central Index Key	0001100397
Document Type	10-Q
Document Period End Date	Apr. 30, 2020
Amendment Flag	false
Current Fiscal Year End Date	--10-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		61,607,580
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2020

Condensed Balance Sheets

Condensed Balance Sheets - USD ($) $ in Thousands	Apr. 30, 2020	Oct. 31, 2019
Current Assets:
Cash and cash equivalents	$ 28,217	$ 32,363
Deferred expenses	1,777	2,353
Prepaid expenses and other current assets	1,774	1,433
Total current assets	31,768	36,149
Property and equipment (net of accumulated depreciation)	3,893	4,350
Intangible assets (net of accumulated amortization)	4,149	4,575
Operating right-of-use asset (net of accumulated amortization)	5,218
Other assets	182	183
Total assets	45,210	45,257
Current liabilities:
Accounts payable	1,530	976
Accrued expenses	1,764	3,478
Common stock warrant liability	40	19
Current portion of operating lease liability	891
Other current liabilities		48
Total current liabilities	4,225	4,521
Operating lease liability, net of current portion	5,548
Other liabilities		1,205
Total liabilities	9,773	5,726
Commitments and contingencies - Note 10
Stockholders' equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; Series B Preferred Stock; 0 shares issued and outstanding at April 30, 2020 and October 31, 2019 Liquidation preference of $0 at April 30, 2020 and October 31, 2019
Common stock - $0.001 par value; 170,000,000 shares authorized, 60,252,444 and 50,201,671 shares issued and outstanding at April 30, 2020 and October 31, 2019, respectively	60	50
Additional paid-in capital	433,826	423,750
Accumulated deficit	(398,449)	(384,269)
Total stockholders' equity	35,437	39,531
Total liabilities and stockholders' equity	$ 45,210	$ 45,257

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Apr. 30, 2020	Oct. 31, 2019
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Preferred stock, liquidation preference value	$ 0	$ 0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	170,000,000	170,000,000
Common stock, shares issued	60,252,444	50,201,671
Common stock, shares outstanding	60,252,444	50,201,671

Condensed Statements of Operati

Condensed Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Apr. 30, 2020	Apr. 30, 2019	Apr. 30, 2020	Apr. 30, 2019
Income Statement [Abstract]
Revenue	$ 250	$ 1,188	$ 253	$ 20,877
Operating expenses:
Research and development expenses	3,922	5,969	8,781	12,675
General and administrative expenses	2,649	3,092	5,679	5,759
Total operating expenses	6,571	9,061	14,460	18,434
(Loss) income from operations	(6,321)	(7,873)	(14,207)	2,443
Other income (expense):
Interest income, net	35	113	101	259
Net changes in fair value of derivative liabilities	14	(14)	(23)	2,395
Loss on shares issued in settlement of warrants		(1,607)		(1,607)
Other expense	(1)	(2)	(1)	(6)
Net (loss) income before benefit for income taxes	(6,273)	(9,383)	(14,130)	3,484
Income tax expense	50		50	50
Net (loss) income	$ (6,323)	$ (9,383)	$ (14,180)	$ 3,434
Net (loss) income per common share
Basic	$ (0.10)	$ (1.59)	$ (0.25)	$ 0.65
Diluted	$ (0.10)	$ (1.59)	$ (0.25)	$ 0.20
Weighted average number of common shares outstanding
Basic	60,572,632	5,900,449	56,107,657	5,259,677
Diluted	60,572,632	5,900,449	56,107,657	5,282,772

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Apr. 30, 2020	Apr. 30, 2019
OPERATING ACTIVITIES
Net (loss) income	$ (14,180)	$ 3,434
Adjustments to reconcile net (loss) income to net cash used in operating activities:
Stock compensation	452	1,101
Employee stock purchase plan expense	1	2
Loss (gain) on change in value of warrants	23	(2,395)
Loss on shares issued in settlement of warrants		1,607
Loss on disposal of property and equipment		2
Abandonment of intangible assets	603	357
Depreciation expense	457	571
Amortization expense of intangible assets	181	193
Amortization of right-of-use asset	365
Change in operating assets and liabilities:
Accounts receivable		1,664
Prepaid expenses and other current assets	235	(994)
Other assets	1
Accounts payable and accrued expenses	(1,161)	(6,675)
Deferred revenue		(18,665)
Operating lease liabilities	(397)
Other liabilities		28
Net cash used in operating activities	(13,420)	(19,770)
INVESTING ACTIVITIES
Purchase of property and equipment		(54)
Proceeds from disposal of property and equipment		8
Cost of intangible assets	(358)	(663)
Net cash used in investing activities	(358)	(709)
FINANCING ACTIVITIES
Net proceeds of issuance of common stock	9,628	8,982
Warrant exercise		68
Proceeds from employee stock purchase plan	4	17
Employee tax withholdings paid on equity awards		(13)
Tax shares sold to pay for employee tax withholdings on equity awards		13
Net cash provided by financing activities	9,632	9,067
Net decrease in cash and cash equivalents	(4,146)	(11,412)
Cash and cash equivalents at beginning of period	32,363	45,118
Cash and cash equivalents at end of period	28,217	33,706
SUPPLEMENTAL CASH FLOW INFORMATION
Cash paid for taxes	50	50
SUPPLEMENTAL DISCLOSURE OF NON-CASH AND FINANCING ACTIVITIES
Shares issued in settlement of warrants		5,463
Warrant liability reclassified into equity	$ 2	$ 53

Nature of Operations

Nature of Operations	6 Months Ended
	Apr. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations	1. NATURE OF OPERATIONS Advaxis, Inc. (“Advaxis” or the “Company”) is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Listeria monocytogenes Lm Lm Lm Lm TM ● Alerting and training the immune system by activating multiple pathways in Antigen-Presenting Cells (“APCs”) with the equivalent of multiple adjuvants; ● Attacking the tumor by generating a strong, cancer-specific T cell response; and ● Breaking down tumor protection through suppression of the protective cells in the tumor microenvironment (“TME”) that shields the tumor from the immune system. This enables the activated T cells to begin working to attack the tumor cells. Advaxis’ proprietary Lm Lm Liquidity and Financial Condition The Company has not yet commercialized any products and the products that are being developed have not generated significant revenue. As a result, the Company has experienced recurring losses and requires significant cash resources to execute its business plans. Historically, the Company’s major sources of cash have been comprised of proceeds from various public and private offerings of its common stock, debt financings, clinical collaborations, option and warrant exercises, NOL tax sales, income earned on investments and grants and interest income. From October 2013 through April 30, 2020, the Company raised approximately $303.8 million in gross proceeds ($11.6 million in fiscal year 2020) from various public and private offerings of its common stock. In Note 2 of the notes to the Company’s audited financial statements as of and for the year ended October 31, 2019, management stated that the Company had incurred significant losses, negative operating cash flows and as of those dates needed to raise additional funds to meet its obligations and sustain its operations. As a result, the Company concluded that there was substantial doubt as to the Company’s ability to continue as a going concern. As of April 30, 2020, the Company had approximately $28 million in cash and cash equivalents. The Company significantly reduced its operating expenses to $38.9 million for the fiscal year ended October 31, 2019 as compared to $76.4 million during the fiscal year ended October 31, 2018. The Company believes to have sufficient capital to fund its obligations, as they become due, in the ordinary course of business until at least August 2021. Given its cash balances including funds raised in fiscal 2020 of $11.6 million (which yielded net proceeds of $10.6 million) and based on its budgeted, reduced cash flow requirements for the next twelve months from the date of filing, the Company believes such funds are sufficient to support ongoing operations at least one year after the issuance of these financial statements.

Summary of Significant Accounti

Summary of Significant Accounting Policies and Basis of Presentation	6 Months Ended
	Apr. 30, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies and Basis of Presentation	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION Basis of Presentation/Estimates The accompanying unaudited interim condensed financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, and in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) with respect to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements and the accompanying unaudited interim condensed balance sheet as of April 30, 2020 has been derived from the Company’s October 31, 2019 audited financial statements. In the opinion of management, the unaudited interim condensed financial statements furnished include all adjustments (consisting of normal recurring accruals) necessary for a fair statement of the results for the interim periods presented. Operating results for interim periods are not necessarily indicative of the results to be expected for the full year. The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Significant estimates include the timelines associated with revenue recognition on upfront payments received, fair value and recoverability of the carrying value of property and equipment and intangible assets, fair value of warrant liability, grant date fair value of options, deferred tax assets and any related valuation allowance and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, based on historical experience and on various other assumptions that it believes to be reasonable under the circumstances. Actual results could materially differ from these estimates. These unaudited interim condensed financial statements should be read in conjunction with the financial statements of the Company as of and for the fiscal year ended October 31, 2019 and notes thereto contained in the Company’s annual report on Form 10-K, as filed with the SEC on December 20, 2019, as amended by Amendment No. 1 thereto on Form 10-K/A filed on January 21, 2020 and by Amendment No. 2 thereto on Form 10-K/A filed on February 28, 2020. Leases Effective November 1, 2019, the Company adopted ASC Topic 842, Leases (“ASC 842”) using the modified retrospective transition approach by applying the new standard to all leases existing as of the date of initial application. Results and disclosure requirements for reporting periods beginning after November 1, 2019 are presented under ASC 842, while prior period amounts have not been adjusted and continue to be reported in accordance with the previous guidance in ASC 840, Leases. At the inception of an arrangement, the Company determines whether an arrangement is or contains a lease based on the facts and circumstances present in the arrangement. An arrangement is or contains a lease if the arrangement conveys the right to control the use of an identified asset for a period of time in exchange for consideration. Most leases with a term greater than one year are recognized on the balance sheet as operating lease right-of-use assets and current and long-term operating lease liabilities, as applicable. The Company has elected not to recognize on the balance sheet leases with terms of 12 months or less. The Company typically only includes the initial lease term in its assessment of a lease arrangement. Options to extend a lease are not included in the Company’s assessment unless there is reasonable certainty that the Company will renew. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as prepaid or accrued rent. The interest rate implicit in the Company’s leases is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. In transition to ASC 842, the Company utilized the remaining lease term of its leases in determining the appropriate incremental borrowing rates. Recent Accounting Standards Recently Adopted Accounting Standards On November 1, 2019, the Company adopted Accounting Standards Update No. 2016-02, Leases (Topic 842) (ASU 2016-02), as amended, which establishes ASC 842 and supersedes the lease accounting guidance under ASC 840, and generally requires lessees to recognize operating and financing lease liabilities and corresponding right-of-use (ROU) assets on the balance sheet and to provide enhanced disclosures surrounding the amount, timing and uncertainty of cash flows arising from leasing arrangements. We adopted the new guidance using the modified retrospective transition approach by applying the new standard to all leases existing at the date of initial application and not restating comparative periods. In adopting the new standard, the Company elected to utilize the available package of practical expedients permitted under the transition guidance within the new standard, which does not require the reassessment of the following: (i) whether existing or expired arrangements are or contain a lease, (ii) the lease classification of existing or expired leases, and (iii) whether previous initial direct costs would qualify for capitalization under the new lease standard. Additionally, the Company elected to combine lease and non-lease components and to exclude leases with a term of 12 months or less. As of the November 1, 2019 effective date, the Company had identified one operating lease arrangement and one short-term lease in which it is a lessee. The adoption of ASC 842 resulted in the recognition of an operating lease liability and a right-of-use asset of approximately $6.8 million and $5.6 million, respectively, on the Company’s balance sheet relating to its leases, with the difference relating to reclassifications of the current accrued rent liability and the current lease incentive obligation of approximately $0.9 million and $0.3 million, respectively, as reductions to the right-of-use-asset for its operating lease. The adoption of the standard did not have a material effect on the Company’s condensed statements of operations or condensed statements of cash flows. Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying condensed financial statements.

Property and Equipment

Property and Equipment	6 Months Ended
	Apr. 30, 2020
Property, Plant and Equipment [Abstract]
Property and Equipment	3. PROPERTY AND EQUIPMENT Property and equipment, net consists of the following (in thousands): April 30, 2020 October 31, 2019 Leasehold improvements $ 2,335 $ 2,335 Laboratory equipment 3,405 3,405 Furniture and fixtures 744 744 Computer equipment 409 409 Construction in progress 83 83 Total property and equipment 6,976 6,976 Accumulated depreciation and amortization (3,083 ) (2,626 ) Net property and equipment $ 3,893 $ 4,350 Depreciation expense for the three months ended April 30, 2020 and 2019 was $0.2 million and $0.3 million, respectively. Depreciation expense for the six months ended April 30, 2020 and 2019 was $0.5 million and $0.6 million, respectively.

Intangible Assets

Intangible Assets	6 Months Ended
	Apr. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	4. INTANGIBLE ASSETS Intangible assets, net consist of the following (in thousands): April 30, 2020 October 31, 2019 Patents $ 5,520 $ 5,833 Licenses 777 777 Software 117 117 Total intangibles 6,414 6,727 Accumulated amortization (2,265 ) (2,152 ) Intangible assets $ 4,149 $ 4,575 The expirations of the existing patents range from 2020 to 2040 but the expirations can be extended based on market approval if granted and/or based on existing laws and regulations. Capitalized costs associated with patent applications that are abandoned without future value are charged to expense when the determination is made not to pursue the application. Patent applications having a net book value of $0.4 million and $0.1 million were abandoned and were charged to research and development expenses in the statement of operations for the three months ended April 30, 2020 and 2019, respectively. Patent applications having a net book value of $0.6 million and $0.4 million were abandoned and were charged to research and development expenses in the statement of operations for the six months ended April 30, 2020 and 2019, respectively. Amortization expense for intangible assets that was charged to general and administrative expense in the statement of operations aggregated $0.1 million for each of the three months ended April 30, 2020 and 2019, respectively. Amortization expense for intangible assets that was charged to general and administrative expense in the statement of operations aggregated $0.2 million for each of the six months ended April 30, 2020 and 2019, respectively. Management has reviewed its long-lived assets for impairment whenever events and circumstances indicate that the carrying value of an asset might not be recoverable. Net assets are recorded on the balance sheet for patents and licenses related to axalimogene filolisbac (AXAL), ADXS-HOT, ADXS-PSA and ADXS-HER2 and other products that are in development. However, if a competitor were to gain FDA approval for a treatment before us or if future clinical trials fail to meet the targeted endpoints, the Company would likely record an impairment related to these assets. In addition, if an application is rejected or fails to be issued, the Company would record an impairment of its estimated book value. Lastly, if the Company is unable to raise enough capital to continue funding its studies and developing its intellectual property, the Company would likely record an impairment to these assets. At April 30, 2020, the estimated amortization expense by fiscal year based on the current carrying value of intangible assets is as follows (in thousands): Fiscal year ending October 31, 2020 (Remaining) $ 167 2021 325 2022 324 2023 324 2024 324 Thereafter 2,685 Total $ 4,149

Accrued Expenses

Accrued Expenses	6 Months Ended
	Apr. 30, 2020
Payables and Accruals [Abstract]
Accrued Expenses	5. ACCRUED EXPENSES: April 30, 2020 October 31, 2019 Salaries and other compensation $ 852 $ 158 Vendors 562 3,194 Professional fees 350 126 Total accrued expenses $ 1,764 $ 3,478

Common Stock Purchase Warrants

Common Stock Purchase Warrants and Warrant Liability	6 Months Ended
	Apr. 30, 2020
Common Stock Purchase Warrants And Warrant Liability
Common Stock Purchase Warrants and Warrant Liability	6. COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY Warrants As of April 30, 2020, there were outstanding warrants to purchase 5,398,226 shares of our common stock with exercise prices ranging from $0 to $281.25 per share. Information on the outstanding warrants is as follows: Exercise Number of Shares Underlying Warrants Expiration Date Type of Financing $ - 327,338 July 2024 July 2019 Public Offering $ 281.25 25 N/A Other warrants $ 0.372 70,863 September 2024 September 2018 Public Offering $ 1.25 5,000,000 July 2025 January 2020 Public Offering Grand Total 5,398,226 As of October 31, 2019, there were outstanding warrants to purchase 432,142 shares of our common stock with exercise prices ranging from $0 to $281.25 per share. Information on the outstanding warrants is as follows: Exercise Number of Shares Underlying Warrants Expiration Date Type of Financing $ - 359,838 July 2024 July 2019 Public Offering $ 281.25 25 N/A Other Warrants $ 0.372 72,279 September 2024 September 2018 Public Offering Grand Total 432,142 A summary of warrant activity was as follows (in thousands, except share and per share data): Shares Weighted Weighted Aggregate Outstanding and exercisable warrants at October 31, 2019 432,142 $ 0.08 4.76 $ 114,069 Issued 5,000,000 1.25 Exercised * (33,916 ) 0.02 Outstanding and exercisable warrants at April 30, 2020 5,398,226 $ 1.16 5.16 $ 240,832 * Includes the cashless exercise of 32,500 warrants that resulted in the issuance of 32,500 shares of common stock. As of April 30, 2020, the Company had 5,327,363 of its total 5,398,226 outstanding warrants classified as equity (equity warrants). At October 31, 2019, the Company had 359,863 of its total 432,142 outstanding warrants classified as equity (equity warrants). At issuance, equity warrants are recorded at their relative fair values, using the relative fair value method, in the stockholders’ equity section of the balance sheet. Warrant Liability As of April 30, 2020, the Company had 70,863 of its total 5,398,226 outstanding warrants classified as liabilities (liability warrants). At October 31, 2019, the Company had 72,279 of its total 432,142 outstanding warrants classified as liabilities (liability warrants). These warrants contain a down round feature, except for exempt issuances as defined in the warrant agreement, in which the exercise price would immediately be reduced to match a dilutive issuance of common stock, options, convertible securities and changes in option price or rate of conversion. As of April 30, 2020, the down round feature was triggered three times and the exercise price of the warrants were reduced from $22.50 to $0.372. The warrants require liability classification as the warrant agreement requires the Company to maintain an effective registration statement and does not specify any circumstances under which settlement in other than cash would be permitted or required. As a result, net cash settlement is assumed and liability classification is warranted. For these liability warrants, the Company utilized the Monte Carlo simulation model to calculate the fair value of these warrants at issuance and at each subsequent reporting date. In measuring the warrant liability at April 30, 2020 and October 31, 2019, the Company used the following inputs in its Monte Carlo simulation model: April 30, 2020 October 31, 2019 Exercise Price $ 0.372 $ 0.372 Stock Price $ 0.67 $ 0.32 Expected Term 4.37 years 4.87 years Volatility % 103.81 % 100.99 % Risk Free Rate 0.36 % 1.51 %

Share Based Compensation

Share Based Compensation	6 Months Ended
	Apr. 30, 2020
Share-based Payment Arrangement [Abstract]
Share Based Compensation	7. SHARE BASED COMPENSATION The following table summarizes share-based compensation expense included in the condensed statement of operations (in thousands): Three Months Ended April 30, Six Months Ended April 30, 2020 2019 2020 2019 Research and development $ 62 $ 258 $ 153 $ 581 General and administrative 148 221 299 520 Total $ 210 $ 479 $ 452 $ 1,101 Restricted Stock Units (RSUs) A summary of the Company’s RSU activity and related information for the six months ended April 30, 2020 is as follows: Number of Weighted-Average Balance at October 31, 2019 14,706 $ 47.62 Vested (8,608 ) 59.61 Cancelled (280 ) 98.80 Balance at April 30, 2020 5,818 $ 27.40 As of April 30, 2020, there was approximately $0.1 million of unrecognized compensation cost related to non-vested RSUs, which is expected to be recognized over a remaining weighted average vesting period of approximately 0.94 years. As of April 30, 2020, the aggregate intrinsic value of non-vested RSU’s was approximately $4,000. Employee Stock Awards Common Stock issued to executives and employees related to vested incentive retention awards, employment inducements, management purchases and employee excellence awards totaled 5,651 shares and 692 shares during the three months ended April 30, 2020 and 2019, respectively. Total stock compensation expense associated with employee awards for the three months ended April 30, 2020 and 2019 was approximately $40,000 and $0.2 million, respectively Common Stock issued to executives and employees related to vested incentive retention awards, employment inducements, management purchases and employee excellence awards totaled 8,608 shares and 10,539 shares during the six months ended April 30, 2020 and 2019, respectively. Total stock compensation expense associated with employee awards for the six months ended April 30, 2020 and 2019 was approximately $0.1 million and $0.5 million, respectively. Stock Options A summary of changes in the stock option plan for the six months ended April 30, 2020 is as follows: Number of Weighted-Average Outstanding at October 31, 2019: 560,490 $ 71.56 Canceled or expired (18,212 ) 13.77 Outstanding at April 30, 2020 542,278 73.50 Vested and Exercisable at April 30, 2020 289,982 $ 132.62 Total compensation cost related to the Company’s outstanding stock options, recognized in the statement of operations for the three months ended April 30, 2020 and 2019 was approximately $0.2 million and $0.3 million, respectively. For the six months ended April 30, 2020 and 2019, compensation cost related to the Company’s outstanding stock options was approximately $0.4 million and $0.6 million, respectively. As of April 30, 2020, there was approximately $0.8 million of unrecognized compensation cost related to non-vested stock option awards, which is expected to be recognized over a remaining weighted average vesting period of approximately 1.17 years. As of April 30, 2020, the aggregate intrinsic value of vested and exercisable options was $0. In determining the fair value of the stock options granted during the six months ended April 30, 2019, the Company used the following inputs in its Black Scholes Merton model: Six Months Ended April 30, 2019 Expected Term 5.50 – 6.51 years Expected Volatility 90.29 – 104.20 % Expected Dividends 0 % Risk Free Interest Rate 2.39 – 3.15 % Employee Stock Purchase Plan During the six months ended April 30, 2020 and 2019, the Company issued 8,249 and 3,512 shares, respectively, that were purchased under the 2018 Employee Stock Purchase Plan (“ESPP”).

Net Income (Loss) Per Share

Net Income (Loss) Per Share	6 Months Ended
	Apr. 30, 2020
Net (loss) income per common share
Net Income (Loss) Per Share	8 NET INCOME (LOSS) PER SHARE Basic and diluted earnings per share is calculated as follows (in thousands, except share and per share data): Three Months Ended April 30, 2020 2019 Numerator: Net loss $ (6,323 ) $ (9,383 ) Loss attributable to common stockholders – basic and diluted (6,323 ) (9,383 ) Denominator: Weighted-average number of common shares used in earnings per share – basic and diluted 60,572,632 5,900,449 Loss per share – basic and diluted $ (0.10 ) $ (1.59 ) Six Months Ended April 30, 2020 2019 Numerator: Net (loss) income $ (14,180 ) $ 3,434 (Loss) income attributable to common stockholders – basic (14,180 ) 3,434 Effect of liability classified warrants - (2,395 ) (Loss) income attributable to common stockholders – diluted (14,180 ) 1,039 Denominator: Weighted-average number of common shares used in earnings per share - basic 56,107,657 5,259,677 Effect of dilutive stock options - 61 Effect of dilutive warrants - 23,034 Weighted-average number of common shares used in earnings per share - diluted 5,282,772 56,107,657 (Loss) income per share – basic $ (0.25 ) $ 0.65 (Loss) income per share – diluted $ (0.25 ) $ 0.20 The following potentially dilutive securities, prior to the use of the treasury stock method, have been excluded from the computation of diluted weighted-average shares outstanding, as they would be anti-dilutive: As of April 30, 2020 2019 Warrants 5,398,226 72,304 Stock options 252,296 235,097 Restricted stock units 5,818 17,063 Total 5,946,322 324,464

Collaboration and Licensing Agr

Collaboration and Licensing Agreements	6 Months Ended
	Apr. 30, 2020
Business Combinations [Abstract]
Collaboration and Licensing Agreements	9. COLLABORATION AND LICENSING AGREEMENTS Elanco Animal Health (formerly Aratana Therapeutics) During the year fiscal year ended October 31, 2018, the USDA’s Center for Veterinary Biologics granted Aratana conditional approval for its canine osteosarcoma vaccine using Advaxis’ technology. During the each of three months ended April 30, 2020 and 2019, Advaxis recognized royalty revenue totaling $0, respectively, from Aratana’s sales of the canine osteosarcoma vaccine. During the six months ended April 30, 2020 and 2019, Advaxis recognized royalty revenue totaling approximately $3,000 and $2,000, respectively, from Aratana’s sales of the canine osteosarcoma vaccine. On July 16, 2019, Aratana announced their shareholders approved a merger agreement with Elanco Animal Health (“Elanco”) whereby Elanco will be the majority shareholder of Aratana. All of the terms of the Aratana Agreement remain in effect. Global BioPharma Inc. On December 9, 2013, the Company entered into an exclusive licensing agreement for the development and commercialization of axalimogene filolisbac with Global BioPharma, Inc. (“GBP”), a Taiwanese based biotech company funded by a group of investors led by Taiwan Biotech Co., Ltd (TBC). During each of the six months ended April 30, 2020 and 2019, the Company recorded $0.3 million in revenue for the annual license fee renewal. Since Advaxis has no significant obligation to perform after the license transfer and has provided GBP with the right to use its intellectual property, performance is satisfied when the license renews.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Apr. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	10. COMMITMENTS AND CONTINGENCIES Legal Proceedings Stendhal On September 19, 2018, Stendhal filed a Demand for Arbitration before the International Centre for Dispute Resolution (Case No. 01-18-0003-5013) relating to the Co-development and Commercialization Agreement with Especificos Stendhal SA de CV (the “Stendhal Agreement”). In the demand, Stendhal alleged that (i) the Company breached the Stendhal Agreement when it made certain statements regarding its AIM2CERV program, (ii) that Stendhal was subsequently entitled to terminate the Agreement for cause, which it did so at the time and (iii) that the Company owes Stendhal damages pursuant to the terms of the Stendhal Agreement. Stendhal is seeking to recover $3 million paid to the Company in 2017 as support payments for the AIM2CERV clinical trial along with approximately $0.3 million in expenses incurred. Stendhal is also seeking fees associated with the arbitration and interest. The Company has answered Stendhal’s Demand for Arbitration and denied that it breached the Stendhal Agreement. The Company also alleges that Stendhal breached its obligations to the Company by, among other things, failing to make support payments that became due in 2018 and that Stendhal therefore owes the Company $3 million. Advaxis is also seeking fees associated with the arbitration and interest. From October 21-23, 2019, an evidentiary hearing for the arbitration was conducted. On April 1, 2020, the Arbitrator issued a final award denying Stendhal’s claim in full. The Arbitrator found that the Company had not repudiated the Agreement and did not owe Stendhal damages, fees, or interest associated with the arbitration. The Arbitrator also denied the Company’s claim that Stendhal breached its obligations to the Company. The parties were ordered to bear their own attorneys’ fees and evenly split administrative fees and expenses for the arbitration.

Leases

Leases	6 Months Ended
	Apr. 30, 2020
Leases [Abstract]
Leases	11. LEASES Operating Leases The Company leases its corporate office and manufacturing facility in Princeton, New Jersey under an operating lease that expires in November 2025. The Company has the option to renew the lease term for two additional five-year terms. The renewal periods were not included the lease term for purposes of determining the lease liability or right-of-use asset. The Company has provided a security deposit of approximately $182,000, which is recorded as Other Assets in the condensed balance sheet. The Company identified and assessed the following significant assumptions in recognizing its right-of-use assets and corresponding lease liabilities: ● As the Company does not have sufficient insight to determine an implicit rate, the Company estimated the incremental borrowing rate in calculating the present value of the lease payments. The Company utilized a synthetic credit rating model to determine a benchmark for its incremental borrowing rate for its leases. The benchmark rate was adjusted to arrive at an appropriate discount rate for the lease. ● Since the Company elected to account for each lease component and its associated non-lease components as a single combined component, all contract consideration was allocated to the combined lease component. ● Renewal option periods have not been included in the determination of the lease terms as they are not deemed reasonably certain of exercise. ● Variable lease payments, such as common area maintenance, real estate taxes, and property insurance are not included in the determination of the lease’s right-of-use asset or lease liability. Supplemental balance sheet information related to leases as of April 30, 2020 was as follows (in thousands): Operating Leases:  Operating lease right-of-use assets $ 5,218 Operating lease liability $ 891 Operating lease liability, net of current portion 5,548 Total operating lease liabilities $ 6,439 Supplemental lease expense related to leases was as follows (in thousands): Lease Cost (in thousands) Statements of Operations Classification For the Three For the Six Operating lease cost General and administrative 289 579 Short-term lease cost General and administrative 85 169 Variable lease cost General and administrative $ 129 $ 270 Total lease expense $ 503 $ 1,018 Other information related to leases where the Company is the lessee is as follows: For the Six Weighted-average remaining lease term 5.6 years Weighted-average discount rate 6.5 % Supplemental cash flow information related to operating leases was as follows: For the Three For the Six Cash paid for operating lease liabilities $ 311 $ 611 Future minimum lease payments under non-cancellable leases as of April 30, 2020 were as follows: Fiscal Year ending October 31, 2020 (Remaining) $ 622 2021 1,318 2022 1,369 2023 1,395 2024 1,419 Thereafter 1,564 Total minimum lease payments 7,687 Less: Imputed interest (1,248 ) Total $ 6,439 Under ASC 840, future minimum payments under the Company’s operating lease were as follows (in thousands): Fiscal Year ending October 31, 2020 $ 1,233 2021 1,318 2022 1,369 2023 1,395 2024 1,419 Thereafter 1,564 Total $ 8,298 Under ASC 840, rent expense for each of the years ended October 31, 2019 and 2018 was approximately $1.2 million.

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Apr. 30, 2020
Equity [Abstract]
Stockholders' Equity	12. STOCKHOLDERS’ EQUITY A summary of the changes in stockholders’ equity for the three and six months ended April 30, 2020 and 2019 is presented below (in thousands, except share data): Preferred Stock Common Stock Additional Accumulated Total Shares Amount Shares Amount Capital Deficit Equity Balance at November 1, 2018 - $ - 4,634,189 $ 5 $ 391,703 $ (367,657 ) $ 24,051 Stock based compensation - - 9,811 - 622 - 622 Tax withholdings paid on equity awards - - - - (11 ) - (11 ) Tax shares sold to pay for tax withholdings on equity awards - - - - 11 - 11 Issuance of shares to employees under ESPP Plan - - 2,007 - 9 - 9 ESPP Expense - - - - 1 1 Net Income - - - - 12,817 12,817 Balance at January 31, 2019 - $ - 4,646,007 $ 5 $ 392,335 $ (354,840 ) $ 37,500 Stock based compensation - - 693 - 479 - 479 Tax withholdings paid on equity awards - - - - (3 ) - (3 ) Tax shares sold to pay for tax withholdings on equity awards - - - - 3 - 3 Issuance of shares to employees under ESPP Plan - - 1,505 - 7 - 7 Warrant exercises - - 15,300 - 68 - 68 Warrant liability reclassified into equity - - - - 53 - 53 ESPP Expense - - - - 1 1 Shares issued in settlement of warrants - - 856,865 1 5,462 - 5,463 Advaxis public offerings - - 2,500,000 2 8,980 - 8,982 Net Loss - - - - - (9,383 ) (9,383 ) Balance at April 30, 2019 - $ - 8,020,370 $ 8 $ 407,385 $ (364,223 ) $ 43,170 Preferred Stock Common Stock Additional Accumulated Total Shares Amount Shares Amount Capital Deficit Equity Balance at November 1, 2019 - $ - 50,201,671 $ 50 $ 423,750 $ (384,269 ) $ 39,531 Stock based compensation - - 2,957 - 242 - 242 Advaxis public offerings - - 10,000,000 10 9,618 - 9,628 Warrant exercises - - 26,416 - 2 - 2 Issuance of shares to employees under ESPP Plan - - 5,555 - 2 - 2 Net Income - - - - - (7,857 ) (7,857 ) Balance at January 31, 2020 - $ - 60,236,599 $ 60 $ 433,614 $ (392,126 ) $ 41,548 Stock based compensation - - 5,651 - 210 - 210 Warrant exercises - - 7,500 - - - - Issuance of shares to employees under ESPP Plan - - 2,694 - 2 - 2 Net Income - - - - - (6,323 ) (6,323 ) Balance at April 30, 2020 - $ - 60,252,444 $ 60 $ 433,826 $ (398,449 ) $ 35,437 On February 21, 2019, the Company’s stockholders voted to approve an amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) increase the number of authorized shares of common stock from 95,000,000 to 170,000,000 and also voted to approve an amendment to the Certificate of Incorporation allow the Company to execute a reverse stock split of common stock at the discretion of the Board of Directors. The amendment to increase the number of authorized shares of common stock became effective upon filing of the amendment with the Secretary of State of the State of Delaware on February 28, 2019. Additionally, on March 29, 2019, the Company executed a 1 for 15 reverse stock split. During April 2019, the Company issued 2,500,000 shares of the Company’s common stock in a public offering at $4.00 per share, less underwriting discounts and commissions. The net proceeds to the Company from the transaction was approximately $9 million. In January 2020, the Company closed on a public offering of 10,000,000 shares of its common stock at a public offering price of $1.05, for gross proceeds of $10.5 million. In addition, the Company also undertook a concurrent private placement of warrants to purchase up to 5,000,000 shares of common stock. The warrants have an exercise price per share of $1.25, are exercisable during the period beginning on the six-month anniversary of the date of its issuance (the “Initial Exercise Date”) and will expire on the fifth anniversary of the Initial Exercise Date. The warrants also provide that if there is no effective registration statement registering, or no current prospectus available for, the issuance or resale of the warrant shares, the warrants may be exercised via a cashless exercise. After deducting the underwriting discounts and commissions and other offering expenses, the net proceeds from the offering were approximately $9.6 million.

Fair Value

Fair Value	6 Months Ended
	Apr. 30, 2020
Fair Value Disclosures [Abstract]
Fair Value	13. FAIR VALUE The authoritative guidance for fair value measurements defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or the most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Market participants are buyers and sellers in the principal market that are (i) independent, (ii) knowledgeable, (iii) able to transact, and (iv) willing to transact. The guidance describes a fair value hierarchy based on the levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following: ● Level 1 — Quoted prices in active markets for identical assets or liabilities. ● Level 2— Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or corroborated by observable market data or substantially the full term of the assets or liabilities. ● Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the value of the assets or liabilities. The following table provides the assets and liabilities carried at fair value measured on a recurring basis as of April 30, 2019 and October 31, 2019 (in thousands): April 30, 2020 Level 1 Level 2 Level 3 Total Common stock warrant liability, warrants exercisable at $0.372 through September 2024 - - $ 40 $ 40 October 31, 2019 Level 1 Level 2 Level 3 Total Common stock warrant liability, warrants exercisable at $0.372 through September 2024 - - $ 19 $ 19 The following table sets forth a summary of the changes in the fair value of the Company’s warrant liabilities: For the Beginning balance $ 19 Warrant exercises (2 ) Change in fair value 23 Ending Balance $ 40

Subsequent Events

Subsequent Events	6 Months Ended
	Apr. 30, 2020
Subsequent Events [Abstract]
Subsequent Events	14. Subsequent Events At the Annual Meeting of Stockholders of the Company held on May 4, 2020, the stockholders ratified and approved an amendment to the Company’s 2015 Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under such Plan from 877,744 shares to 6,000,000 shares. On May 4, 2020, the Company granted to directors, officers and employees options to purchase 450,000 shares of common stock. The options are priced at $0.66, vest annually in equal installments such that 100% of the options will by the third anniversary of the grant date. The stock options vest one-third after the one year anniversary, one-third after the two year anniversary and one-third after the three year anniversary. At-the-Market Transactions On May 8, 2020, the Company filed a prospectus supplement and associated sales agreement related to an at-the-market (“ATM”) equity offering program pursuant to which the Company may sell, from time to time, common stock with an aggregate offering price of up to $40 million through A.G.P./Alliance Global Partners, as sales agent, for general corporate purposes. From May 8, 2020 through the date the financial statements were issued, the Company sold 1,353,237 shares of its common stock under the ATM program for $1.067 million, or an average of $0.79 per share, and received proceeds of $1.033 million, net of commissions of $34,000.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies and Basis of Presentation (Policies)	6 Months Ended
	Apr. 30, 2020
Accounting Policies [Abstract]
Basis of Presentation/Estimates	Basis of Presentation/Estimates The accompanying unaudited interim condensed financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, and in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) with respect to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements and the accompanying unaudited interim condensed balance sheet as of April 30, 2020 has been derived from the Company’s October 31, 2019 audited financial statements. In the opinion of management, the unaudited interim condensed financial statements furnished include all adjustments (consisting of normal recurring accruals) necessary for a fair statement of the results for the interim periods presented. Operating results for interim periods are not necessarily indicative of the results to be expected for the full year. The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Significant estimates include the timelines associated with revenue recognition on upfront payments received, fair value and recoverability of the carrying value of property and equipment and intangible assets, fair value of warrant liability, grant date fair value of options, deferred tax assets and any related valuation allowance and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, based on historical experience and on various other assumptions that it believes to be reasonable under the circumstances. Actual results could materially differ from these estimates. These unaudited interim condensed financial statements should be read in conjunction with the financial statements of the Company as of and for the fiscal year ended October 31, 2019 and notes thereto contained in the Company’s annual report on Form 10-K, as filed with the SEC on December 20, 2019, as amended by Amendment No. 1 thereto on Form 10-K/A filed on January 21, 2020 and by Amendment No. 2 thereto on Form 10-K/A filed on February 28, 2020.
Leases	Leases Effective November 1, 2019, the Company adopted ASC Topic 842, Leases (“ASC 842”) using the modified retrospective transition approach by applying the new standard to all leases existing as of the date of initial application. Results and disclosure requirements for reporting periods beginning after November 1, 2019 are presented under ASC 842, while prior period amounts have not been adjusted and continue to be reported in accordance with the previous guidance in ASC 840, Leases. At the inception of an arrangement, the Company determines whether an arrangement is or contains a lease based on the facts and circumstances present in the arrangement. An arrangement is or contains a lease if the arrangement conveys the right to control the use of an identified asset for a period of time in exchange for consideration. Most leases with a term greater than one year are recognized on the balance sheet as operating lease right-of-use assets and current and long-term operating lease liabilities, as applicable. The Company has elected not to recognize on the balance sheet leases with terms of 12 months or less. The Company typically only includes the initial lease term in its assessment of a lease arrangement. Options to extend a lease are not included in the Company’s assessment unless there is reasonable certainty that the Company will renew. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as prepaid or accrued rent. The interest rate implicit in the Company’s leases is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. In transition to ASC 842, the Company utilized the remaining lease term of its leases in determining the appropriate incremental borrowing rates.
Recent Accounting Standards	Recent Accounting Standards Recently Adopted Accounting Standards On November 1, 2019, the Company adopted Accounting Standards Update No. 2016-02, Leases (Topic 842) (ASU 2016-02), as amended, which establishes ASC 842 and supersedes the lease accounting guidance under ASC 840, and generally requires lessees to recognize operating and financing lease liabilities and corresponding right-of-use (ROU) assets on the balance sheet and to provide enhanced disclosures surrounding the amount, timing and uncertainty of cash flows arising from leasing arrangements. We adopted the new guidance using the modified retrospective transition approach by applying the new standard to all leases existing at the date of initial application and not restating comparative periods. In adopting the new standard, the Company elected to utilize the available package of practical expedients permitted under the transition guidance within the new standard, which does not require the reassessment of the following: (i) whether existing or expired arrangements are or contain a lease, (ii) the lease classification of existing or expired leases, and (iii) whether previous initial direct costs would qualify for capitalization under the new lease standard. Additionally, the Company elected to combine lease and non-lease components and to exclude leases with a term of 12 months or less. As of the November 1, 2019 effective date, the Company had identified one operating lease arrangement and one short-term lease in which it is a lessee. The adoption of ASC 842 resulted in the recognition of an operating lease liability and a right-of-use asset of approximately $6.8 million and $5.6 million, respectively, on the Company’s balance sheet relating to its leases, with the difference relating to reclassifications of the current accrued rent liability and the current lease incentive obligation of approximately $0.9 million and $0.3 million, respectively, as reductions to the right-of-use-asset for its operating lease. The adoption of the standard did not have a material effect on the Company’s condensed statements of operations or condensed statements of cash flows. Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying condensed financial statements.

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
	Apr. 30, 2020
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment, net consists of the following (in thousands): April 30, 2020 October 31, 2019 Leasehold improvements $ 2,335 $ 2,335 Laboratory equipment 3,405 3,405 Furniture and fixtures 744 744 Computer equipment 409 409 Construction in progress 83 83 Total property and equipment 6,976 6,976 Accumulated depreciation and amortization (3,083 ) (2,626 ) Net property and equipment $ 3,893 $ 4,350

Intangible Assets (Tables)

Intangible Assets (Tables)	6 Months Ended
	Apr. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of Intangible Assets	Intangible assets, net consist of the following (in thousands): April 30, 2020 October 31, 2019 Patents $ 5,520 $ 5,833 Licenses 777 777 Software 117 117 Total intangibles 6,414 6,727 Accumulated amortization (2,265 ) (2,152 ) Intangible assets $ 4,149 $ 4,575
Schedule of Carrying Value of Intangible Assets	At April 30, 2020, the estimated amortization expense by fiscal year based on the current carrying value of intangible assets is as follows (in thousands): Fiscal year ending October 31, 2020 (Remaining) $ 167 2021 325 2022 324 2023 324 2024 324 Thereafter 2,685 Total $ 4,149

Accrued Expenses (Tables)

Accrued Expenses (Tables)	6 Months Ended
	Apr. 30, 2020
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	April 30, 2020 October 31, 2019 Salaries and other compensation $ 852 $ 158 Vendors 562 3,194 Professional fees 350 126 Total accrued expenses $ 1,764 $ 3,478

Common Stock Purchase Warrant_2

Common Stock Purchase Warrants and Warrant Liability (Tables)	6 Months Ended
	Apr. 30, 2020
Common Stock Purchase Warrants And Warrant Liability
Schedule of Outstanding Warrants	As of April 30, 2020, there were outstanding warrants to purchase 5,398,226 shares of our common stock with exercise prices ranging from $0 to $281.25 per share. Information on the outstanding warrants is as follows: Exercise Number of Shares Underlying Warrants Expiration Date Type of Financing $ - 327,338 July 2024 July 2019 Public Offering $ 281.25 25 N/A Other warrants $ 0.372 70,863 September 2024 September 2018 Public Offering $ 1.25 5,000,000 July 2025 January 2020 Public Offering Grand Total 5,398,226 As of October 31, 2019, there were outstanding warrants to purchase 432,142 shares of our common stock with exercise prices ranging from $0 to $281.25 per share. Information on the outstanding warrants is as follows: Exercise Number of Shares Underlying Warrants Expiration Date Type of Financing $ - 359,838 July 2024 July 2019 Public Offering $ 281.25 25 N/A Other Warrants $ 0.372 72,279 September 2024 September 2018 Public Offering Grand Total 432,142
Schedule of Warrants Activity	A summary of warrant activity was as follows (in thousands, except share and per share data): Shares Weighted Weighted Aggregate Outstanding and exercisable warrants at October 31, 2019 432,142 $ 0.08 4.76 $ 114,069 Issued 5,000,000 1.25 Exercised * (33,916 ) 0.02 Outstanding and exercisable warrants at April 30, 2020 5,398,226 $ 1.16 5.16 $ 240,832 * Includes the cashless exercise of 32,500 warrants that resulted in the issuance of 32,500 shares of common stock.
Schedule of Assumptions Used in Warrant Liability	In measuring the warrant liability at April 30, 2020 and October 31, 2019, the Company used the following inputs in its Monte Carlo simulation model: April 30, 2020 October 31, 2019 Exercise Price $ 0.372 $ 0.372 Stock Price $ 0.67 $ 0.32 Expected Term 4.37 years 4.87 years Volatility % 103.81 % 100.99 % Risk Free Rate 0.36 % 1.51 %

Share Based Compensation (Table

Share Based Compensation (Tables)	6 Months Ended
	Apr. 30, 2020
Share-based Payment Arrangement [Abstract]
Summary of Share Based Compensation Expense	The following table summarizes share-based compensation expense included in the condensed statement of operations (in thousands): Three Months Ended April 30, Six Months Ended April 30, 2020 2019 2020 2019 Research and development $ 62 $ 258 $ 153 $ 581 General and administrative 148 221 299 520 Total $ 210 $ 479 $ 452 $ 1,101
Summary of RSU Activity and Related Information	A summary of the Company’s RSU activity and related information for the six months ended April 30, 2020 is as follows: Number of Weighted-Average Balance at October 31, 2019 14,706 $ 47.62 Vested (8,608 ) 59.61 Cancelled (280 ) 98.80 Balance at April 30, 2020 5,818 $ 27.40
Summary of Changes in Stock Option Plan	A summary of changes in the stock option plan for the six months ended April 30, 2020 is as follows: Number of Weighted-Average Outstanding at October 31, 2019: 560,490 $ 71.56 Canceled or expired (18,212 ) 13.77 Outstanding at April 30, 2020 542,278 73.50 Vested and Exercisable at April 30, 2020 289,982 $ 132.62
Summary of Fair Value of Stock Options Granted of BSM	In determining the fair value of the stock options granted during the six months ended April 30, 2019, the Company used the following inputs in its Black Scholes Merton model: Six Months Ended April 30, 2019 Expected Term 5.50 – 6.51 years Expected Volatility 90.29 – 104.20 % Expected Dividends 0 % Risk Free Interest Rate 2.39 – 3.15 %

Net Income (Loss) Per Share (Ta

Net Income (Loss) Per Share (Tables)	6 Months Ended
	Apr. 30, 2020
Net (loss) income per common share
Schedule of Basic and Diluted Earnings Per Share	Basic and diluted earnings per share is calculated as follows (in thousands, except share and per share data): Three Months Ended April 30, 2020 2019 Numerator: Net loss $ (6,323 ) $ (9,383 ) Loss attributable to common stockholders – basic and diluted (6,323 ) (9,383 ) Denominator: Weighted-average number of common shares used in earnings per share – basic and diluted 60,572,632 5,900,449 Loss per share – basic and diluted $ (0.10 ) $ (1.59 ) Six Months Ended April 30, 2020 2019 Numerator: Net (loss) income $ (14,180 ) $ 3,434 (Loss) income attributable to common stockholders – basic (14,180 ) 3,434 Effect of liability classified warrants - (2,395 ) (Loss) income attributable to common stockholders – diluted (14,180 ) 1,039 Denominator: Weighted-average number of common shares used in earnings per share - basic 56,107,657 5,259,677 Effect of dilutive stock options - 61 Effect of dilutive warrants - 23,034 Weighted-average number of common shares used in earnings per share - diluted 5,282,772 56,107,657 (Loss) income per share – basic $ (0.25 ) $ 0.65 (Loss) income per share – diluted $ (0.25 ) $ 0.20
Schedule of Diluted Weighted-Average Shares Outstanding	The following potentially dilutive securities, prior to the use of the treasury stock method, have been excluded from the computation of diluted weighted-average shares outstanding, as they would be anti-dilutive: As of April 30, 2020 2019 Warrants 5,398,226 72,304 Stock options 252,296 235,097 Restricted stock units 5,818 17,063 Total 5,946,322 324,464

Leases (Tables)

Leases (Tables)	6 Months Ended
	Apr. 30, 2020
Leases [Abstract]
Schedule of Supplemental Balance Sheet Related to Leases	Supplemental balance sheet information related to leases as of April 30, 2020 was as follows (in thousands): Operating Leases:  Operating lease right-of-use assets $ 5,218 Operating lease liability $ 891 Operating lease liability, net of current portion 5,548 Total operating lease liabilities $ 6,439
Schedule of Lease Expenses	Supplemental lease expense related to leases was as follows (in thousands): Lease Cost (in thousands) Statements of Operations Classification For the Three For the Six Operating lease cost General and administrative 289 579 Short-term lease cost General and administrative 85 169 Variable lease cost General and administrative $ 129 $ 270 Total lease expense $ 503 $ 1,018
Schedule of Other Information Related to Leases	Other information related to leases where the Company is the lessee is as follows: For the Six Weighted-average remaining lease term 5.6 years Weighted-average discount rate 6.5 %
Schedule of Cash Flow Information Related to Leases	Supplemental cash flow information related to operating leases was as follows: For the Three For the Six Cash paid for operating lease liabilities $ 311 $ 611
Schedule of Future Minimum Lease Payments Under Non-Cancellable Leases	Future minimum lease payments under non-cancellable leases as of April 30, 2020 were as follows: Fiscal Year ending October 31, 2020 (Remaining) $ 622 2021 1,318 2022 1,369 2023 1,395 2024 1,419 Thereafter 1,564 Total minimum lease payments 7,687 Less: Imputed interest (1,248 ) Total $ 6,439
Schedule of Future Minimum Payments Under Operating Lease	Under ASC 840, future minimum payments under the Company’s operating lease were as follows (in thousands): Fiscal Year ending October 31, 2020 $ 1,233 2021 1,318 2022 1,369 2023 1,395 2024 1,419 Thereafter 1,564 Total $ 8,298

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	6 Months Ended
	Apr. 30, 2020
Equity [Abstract]
Summary of Stockholders Equity	A summary of the changes in stockholders’ equity for the three and six months ended April 30, 2020 and 2019 is presented below (in thousands, except share data): Preferred Stock Common Stock Additional Accumulated Total Shares Amount Shares Amount Capital Deficit Equity Balance at November 1, 2018 - $ - 4,634,189 $ 5 $ 391,703 $ (367,657 ) $ 24,051 Stock based compensation - - 9,811 - 622 - 622 Tax withholdings paid on equity awards - - - - (11 ) - (11 ) Tax shares sold to pay for tax withholdings on equity awards - - - - 11 - 11 Issuance of shares to employees under ESPP Plan - - 2,007 - 9 - 9 ESPP Expense - - - - 1 1 Net Income - - - - 12,817 12,817 Balance at January 31, 2019 - $ - 4,646,007 $ 5 $ 392,335 $ (354,840 ) $ 37,500 Stock based compensation - - 693 - 479 - 479 Tax withholdings paid on equity awards - - - - (3 ) - (3 ) Tax shares sold to pay for tax withholdings on equity awards - - - - 3 - 3 Issuance of shares to employees under ESPP Plan - - 1,505 - 7 - 7 Warrant exercises - - 15,300 - 68 - 68 Warrant liability reclassified into equity - - - - 53 - 53 ESPP Expense - - - - 1 1 Shares issued in settlement of warrants - - 856,865 1 5,462 - 5,463 Advaxis public offerings - - 2,500,000 2 8,980 - 8,982 Net Loss - - - - - (9,383 ) (9,383 ) Balance at April 30, 2019 - $ - 8,020,370 $ 8 $ 407,385 $ (364,223 ) $ 43,170 Preferred Stock Common Stock Additional Accumulated Total Shares Amount Shares Amount Capital Deficit Equity Balance at November 1, 2019 - $ - 50,201,671 $ 50 $ 423,750 $ (384,269 ) $ 39,531 Stock based compensation - - 2,957 - 242 - 242 Advaxis public offerings - - 10,000,000 10 9,618 - 9,628 Warrant exercises - - 26,416 - 2 - 2 Issuance of shares to employees under ESPP Plan - - 5,555 - 2 - 2 Net Income - - - - - (7,857 ) (7,857 ) Balance at January 31, 2020 - $ - 60,236,599 $ 60 $ 433,614 $ (392,126 ) $ 41,548 Stock based compensation - - 5,651 - 210 - 210 Warrant exercises - - 7,500 - - - - Issuance of shares to employees under ESPP Plan - - 2,694 - 2 - 2 Net Income - - - - - (6,323 ) (6,323 ) Balance at April 30, 2020 - $ - 60,252,444 $ 60 $ 433,826 $ (398,449 ) $ 35,437

Fair Value (Tables)

Fair Value (Tables)	6 Months Ended
	Apr. 30, 2020
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following table provides the assets and liabilities carried at fair value measured on a recurring basis as of April 30, 2019 and October 31, 2019 (in thousands): April 30, 2020 Level 1 Level 2 Level 3 Total Common stock warrant liability, warrants exercisable at $0.372 through September 2024 - - $ 40 $ 40 October 31, 2019 Level 1 Level 2 Level 3 Total Common stock warrant liability, warrants exercisable at $0.372 through September 2024 - - $ 19 $ 19
Schedule of Changes in Fair Value of Warrant Liabilities	The following table sets forth a summary of the changes in the fair value of the Company’s warrant liabilities: For the Beginning balance $ 19 Warrant exercises (2 ) Change in fair value 23 Ending Balance $ 40

Nature of Operations (Details N

Nature of Operations (Details Narrative) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended		79 Months Ended
	Jan. 31, 2020	Apr. 30, 2020	Apr. 30, 2019	Apr. 30, 2020	Apr. 30, 2019	Oct. 31, 2019	Oct. 31, 2018	Apr. 30, 2020	Apr. 20, 2020
Proceeds from public offering	$ 9,600			$ 11,600				$ 303,800
Cash and cash equivalents		$ 28,217		28,217		$ 32,363		$ 28,217
Operating expenses		$ 6,571	$ 9,061	14,460	$ 18,434	$ 38,900	$ 76,400
Fiscal Year 2020 [Member]
Cash balance funds raised									$ 11,600
Proceeds from cash balance funds				$ 10,600

Summary of Significant Accoun_3

Summary of Significant Accounting Policies and Basis of Presentation (Details Narrative) - USD ($) $ in Thousands	Apr. 30, 2020	Nov. 02, 2019	Oct. 31, 2019
Operating lease liability	$ 891
Right to use asset	$ 5,218
ASC 842 [Member]
Operating lease liability		$ 6,800
Right to use asset		5,600
Accrued rent liability, current		900
Lease incentive obligation, current		$ 300

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Apr. 30, 2020	Apr. 30, 2019	Apr. 30, 2020	Apr. 30, 2019
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 200	$ 300	$ 457	$ 571

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Apr. 30, 2020	Oct. 31, 2019
Property, Plant and Equipment [Abstract]
Leasehold improvements	$ 2,335	$ 2,335
Laboratory equipment	3,405	3,405
Furniture and fixtures	744	744
Computer equipment	409	409
Construction in progress	83	83
Total property and equipment	6,976	6,976
Accumulated depreciation and amortization	(3,083)	(2,626)
Net property and equipment	$ 3,893	$ 4,350

Intangible Assets (Details Narr

Intangible Assets (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Apr. 30, 2020	Apr. 30, 2019	Apr. 30, 2020	Apr. 30, 2019
Finite lived patents expirations year			The expirations of the existing patents range from 2020 to 2040
Book value patent applications, net			$ 603	$ 357
Intangible asset amortization expense			181	193
Research and Development [Member]
Book value patent applications, net	$ 400	$ 100	600	400
General and Administrative [Member]
Intangible asset amortization expense	$ 100	$ 100	$ 200	$ 200

Intangible Assets - Summary of

Intangible Assets - Summary of Intangible Assets (Details) - USD ($) $ in Thousands	Apr. 30, 2020	Oct. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Patents	$ 5,520	$ 5,833
Licenses	777	777
Software	117	117
Total intangibles	6,414	6,727
Accumulated amortization	(2,265)	(2,152)
Intangible assets	$ 4,149	$ 4,575

Intangible Assets - Schedule of

Intangible Assets - Schedule of Carrying Value of Intangible Assets (Details) $ in Thousands	Apr. 30, 2020USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2020 (Remaining)	$ 167
2021	325
2022	324
2023	324
2024	324
Thereafter	2,685
Total	$ 4,149

Accrued Expenses - Schedule of

Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands	Apr. 30, 2020	Oct. 31, 2019
Payables and Accruals [Abstract]
Salaries and other compensation	$ 852	$ 158
Vendors	562	3,194
Professional fees	350	126
Total accrued expenses	$ 1,764	$ 3,478

Common Stock Purchase Warrant_3

Common Stock Purchase Warrants and Warrant Liability (Details Narrative) - $ / shares	Apr. 30, 2020	Oct. 31, 2019
Class of Warrant or Right [Line Items]
Number of warrants to purchase common stock	5,398,226	432,142
Warrant exercise price per share	$ 0.372	$ 0.372
Equity Warrants [Member]
Class of Warrant or Right [Line Items]
Number of warrants to purchase common stock	5,327,363	359,863
Warrants outstanding	5,398,226	432,142
Warrant Liability [Member]
Class of Warrant or Right [Line Items]
Number of warrants to purchase common stock	70,863	72,279
Warrants outstanding	5,398,226	432,142
Minimum [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price per share	$ 0	$ 0
Minimum [Member] | Warrant Liability [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price per share	0.372
Maximum [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price per share	281.25	$ 281.25
Maximum [Member] | Warrant Liability [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price per share	$ 22.50

Common Stock Purchase Warrant_4

Common Stock Purchase Warrants and Warrant Liability - Schedule of Outstanding Warrants (Details) - $ / shares	6 Months Ended	12 Months Ended
	Apr. 30, 2020	Oct. 31, 2019
Class of Warrant or Right [Line Items]
Exercise Price	$ 0.372	$ 0.372
Number of Shares Underlying Warrants	5,398,226	432,142
Exercise Price Range One [Member]
Class of Warrant or Right [Line Items]
Exercise Price
Number of Shares Underlying Warrants	327,338	359,838
Expiration Date	Jul. 31, 2024	Jul. 31, 2024
Summary of Warrants	July 2019 Public Offering	July 2019 Public Offering
Exercise Price Range Two [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 281.25	$ 281.25
Number of Shares Underlying Warrants	25	25
Summary of Warrants	Other Warrants	Other Warrants
Exercise Price Range Three [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 0.372	$ 0.372
Number of Shares Underlying Warrants	70,863	72,279
Expiration Date	Sep. 30, 2024	Sep. 30, 2024
Summary of Warrants	September 2018 Public Offering	September 2018 Public Offering
Exercise Price Range Four [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 1.25
Number of Shares Underlying Warrants	5,000,000
Expiration Date	Jul. 31, 2025
Summary of Warrants	January 2020 Public Offering

Common Stock Purchase Warrant_5

Common Stock Purchase Warrants and Warrant Liability - Schedule of Warrants Activity (Details) $ / shares in Units, $ in Thousands	6 Months Ended
	Apr. 30, 2020USD ($)$ / sharesshares
Common Stock Purchase Warrants And Warrant Liability
Number of Warrants, Outstanding and exercisable warrants, Beginning balance | shares	432,142
Number of Warrants, Issued | shares	5,000,000
Number of Warrants, Exercised | shares	(33,916)	[1]
Number of Warrants, Outstanding and exercisable warrants, Ending balance | shares	5,398,226
Weighted Average Exercise Price, Outstanding and exercisable warrants, Beginning | $ / shares	$ 0.08
Weighted Average Exercise Price, Issued | $ / shares	1.25
Weighted Average Exercise Price, Exercised | $ / shares	0.02	[1]
Weighted Average Exercise Price, Outstanding and exercisable warrants, Ending | $ / shares	$ 1.16
Weighted Average Remaining Contractual Life In Years, Outstanding and exercisable warrants, Beginning	4 years 9 months 3 days
Weighted Average Remaining Contractual Life In Years, Outstanding and exercisable warrants, Ending balance	5 years 1 month 27 days
Aggregate Intrinsic Value, Beginning | $	$ 114,069
Aggregate Intrinsic Value, Ending | $	$ 240,832
[1]	Includes the cashless exercise of 32,500 warrants that resulted in the issuance of 32,500 shares of common stock.

Common Stock Purchase Warrant_6

Common Stock Purchase Warrants and Warrant Liability - Schedule of Warrants Activity (Details) (Parenthetical)	6 Months Ended
	Apr. 30, 2020shares
Common Stock Purchase Warrants And Warrant Liability
Cashless warrant exercise	32,500
Number of common stock shares issued	32,500

Common Stock Purchase Warrant_7

Common Stock Purchase Warrants and Warrant Liability - Schedule of Assumptions Used in Warrant Liability (Details)	Apr. 30, 2020$ / shares	Oct. 31, 2019$ / shares
Class of Warrant or Right [Line Items]
Warrants exercise price	$ 0.372	$ 0.372
Warrant Liability [Member] | Exercise Price [Member]
Class of Warrant or Right [Line Items]
Warrants exercise price	0.372	0.372
Warrant Liability [Member] | Stock Price [Member]
Class of Warrant or Right [Line Items]
Warrant stock price	$ 0.67	$ 0.32
Warrant Liability [Member] | Expected Term [Member]
Class of Warrant or Right [Line Items]
Warrants, term	4 years 4 months 13 days	4 years 10 months 14 days
Warrant Liability [Member] | Volatility [Member]
Class of Warrant or Right [Line Items]
Warrants, measurement input	103.81	100.99
Warrant Liability [Member] | Risk Free Interest Rate [Member]
Class of Warrant or Right [Line Items]
Warrants, measurement input	0.36	1.51

Share Based Compensation (Detai

Share Based Compensation (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Apr. 30, 2020	Apr. 30, 2019	Apr. 30, 2020	Apr. 30, 2019
Unrecognized compensation cost related to non-vested stock option awards	$ 800		$ 800
Unrecognized compensation cost related to non-vested remaining weighted average vesting period			1 year 2 months 1 day
Aggregate intrinsic value of non-vested RSU	0		$ 0
Share-based compensation, common stock, shares		479
Stock compensation expense	210	$ 479	452	$ 1,101
Compensation cost related to outstanding stock options	200	$ 300	$ 400	$ 600
Number of shares issued under employee stock purchase plan		7
2018 Employee Stock Purchase Plan [Member]
Number of shares issued under employee stock purchase plan			8,249	3,512
Restricted Stock Units (RSUs) [Member]
Unrecognized compensation cost related to non-vested stock option awards	100		$ 100
Unrecognized compensation cost related to non-vested remaining weighted average vesting period			11 months 8 days
Aggregate intrinsic value of non-vested RSU	$ 4		$ 4
Employee Stock Awards [Member]
Share-based compensation, common stock, shares	5,651	692	8,608	10,539
Stock compensation expense	$ 40	$ 200	$ 100	$ 500

Share Based Compensation - Summ

Share Based Compensation - Summary of Share Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Apr. 30, 2020	Apr. 30, 2019	Apr. 30, 2020	Apr. 30, 2019
Share-based compensation expense	$ 210	$ 479	$ 452	$ 1,101
Research and Development [Member]
Share-based compensation expense	62	258	153	581
General and Administrative [Member]
Share-based compensation expense	$ 148	$ 221	$ 299	$ 520

Share Based Compensation - Su_2

Share Based Compensation - Summary of RSU Activity and Related Information (Details) - Restricted Stock Units (RSUs) [Member]	6 Months Ended
	Apr. 30, 2020$ / sharesshares
Number of RSUs, Unvested Beginning Balance | shares	14,706
Number of RSUs, Vested | shares	(8,608)
Number of RSUs, Cancelled | shares	(280)
Number of RSUs, Unvested Ending Balance | shares	5,818
Weighted-Average Grant Date Fair Value, Unvested Beginning Balance | $ / shares	$ 47.62
Weighted-Average Grant Date Fair Value, Vested | $ / shares	59.61
Weighted-Average Grant Date Fair Value, Cancelled | $ / shares	98.80
Weighted-Average Grant Date Fair Value, Unvested Ending Balance | $ / shares	$ 27.40

Share Based Compensation - Su_3

Share Based Compensation - Summary of Changes in Stock Option Plan (Details)	6 Months Ended
	Apr. 30, 2020$ / sharesshares
Share-based Payment Arrangement [Abstract]
Number of Options, Beginning Balance | shares	560,490
Number of Options, Cancelled or Expired | shares	(18,212)
Number of Options, Ending Balance | shares	542,278
Number of Options, Vested and Exercisable | shares	289,982
Weighted-Average Exercise Price, Outstanding, Beginning | $ / shares	$ 71.56
Weighted-Average Exercise Price, Cancelled or Expired | $ / shares	13.77
Weighted-Average Exercise Price, Outstanding, Ending | $ / shares	73.50
Weighted-Average Exercise Price, Vested and Exercisable | $ / shares	$ 132.62

Share Based Compensation - Su_4

Share Based Compensation - Summary of Fair Value of Stock Options Granted of BSM (Details)	6 Months Ended
	Apr. 30, 2020
Expected Dividends	0.00%
Minimum [Member]
Expected Term	5 years 6 months
Expected Volatility	90.29%
Risk Free Interest Rate	2.39%
Maximum [Member]
Expected Term	6 years 6 months 3 days
Expected Volatility	104.20%
Risk Free Interest Rate	3.15%

Net Income (Loss) Per Share - S

Net Income (Loss) Per Share - Schedule of Basic and Diluted Earnings Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended				6 Months Ended
	Apr. 30, 2020	Jan. 31, 2020	Apr. 30, 2019	Jan. 31, 2019	Apr. 30, 2020	Apr. 30, 2019
Net (loss) income per common share
Net (loss) income	$ (6,323)	$ (7,857)	$ (9,383)	$ 12,817	$ (14,180)	$ 3,434
Loss attributable to common stockholders - basic and diluted	$ (6,323)		$ (9,383)
(Loss) income attributable to common stockholders - basic					(14,180)	3,434
Effect of liability classified warrants						(2,395)
(Loss) income attributable to common stockholders - diluted					$ (14,180)	$ 1,039
Weighted-average number of common shares used in earnings per share - basic	60,572,632		5,900,449		56,107,657	5,259,677
Effect of dilutive stock options						$ 61
Effect of dilutive warrants						$ 23,034
Weighted-average number of common shares used in earnings per share - diluted	60,572,632		5,900,449		56,107,657	5,282,772
Loss per share - basic and diluted	$ (0.10)		$ (1.59)
(Loss) income per share - basic	(0.10)		(1.59)		$ (0.25)	$ 0.65
(Loss) income per share - diluted	$ (0.10)		$ (1.59)		$ (0.25)	$ 0.20

Net Income (Loss) Per Share -_2

Net Income (Loss) Per Share - Schedule of Diluted Weighted-Average Shares Outstanding (Details) - shares	6 Months Ended
	Apr. 30, 2020	Apr. 30, 2019
Total	5,946,322	324,464
Warrants [Member]
Total	5,398,226	72,304
Stock Options [Member]
Total	252,296	235,097
Restricted Stock Units [Member]
Total	5,818	17,063

Collaboration and Licensing A_2

Collaboration and Licensing Agreements (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Apr. 30, 2020	Apr. 30, 2019	Apr. 30, 2020	Apr. 30, 2019
Revenue	$ 250	$ 1,188	$ 253	$ 20,877
Aratana Agreement [Member] | Royalty [Member]
Revenue	$ 0	$ 0	3	2
Exclusive Licensing Agreement [Member] | License [Member]
Revenue			$ 300	$ 300

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - Especificos Stendhal SA de CV [Member] $ in Thousands	Sep. 19, 2018USD ($)
Damages sought value by plaintiff	$ 3,000
Litigation expense	300
Due from related party	$ 3,000

Leases (Details Narrative)

Leases (Details Narrative) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Apr. 30, 2020	Oct. 31, 2019	Oct. 31, 2018
Leases [Abstract]
Operating lease expiration	Nov. 30, 2025
Security deposit	$ 182
Rent expense		$ 1,200	$ 1,200

Leases - Schedule of Supplement

Leases - Schedule of Supplemental Balance Sheet Related to Leases (Details) - USD ($) $ in Thousands	Apr. 30, 2020	Oct. 31, 2019
Leases [Abstract]
Operating lease right-of-use assets	$ 5,218
Operating lease liability	891
Operating lease liability, net of current portion	5,548
Total operating lease liabilities	$ 6,439

Leases - Schedule of Lease Expe

Leases - Schedule of Lease Expenses (Details) - General and Administrative [Member] - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Apr. 30, 2020	Apr. 30, 2020
Operating lease cost	$ 289	$ 579
Short-term lease cost	85	169
Variable lease cost	129	270
Total lease expense	$ 503	$ 1,018

Leases - Schedule of Other Info

Leases - Schedule of Other Information Related to Leases (Details)	Apr. 30, 2020
Leases [Abstract]
Weighted-average remaining lease term	5 years 7 months 6 days
Weighted-average discount rate	6.50%

Leases - Schedule of Cash Flow

Leases - Schedule of Cash Flow Information Related to Leases (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Apr. 30, 2020	Apr. 30, 2020
Leases [Abstract]
Cash paid for operating lease liabilities	$ 311	$ 611

Leases - Schedule of Future Min

Leases - Schedule of Future Minimum Lease Payments Under Non-Cancellable Leases (Details) $ in Thousands	Apr. 30, 2020USD ($)
Leases [Abstract]
2020 (Remaining)	$ 622
2021	1,318
2022	1,369
2023	1,395
2024	1,419
Thereafter	1,564
Total minimum lease payments	7,687
Less: Imputed interest	(1,248)
Total	$ 6,439

Leases - Schedule of Future M_2

Leases - Schedule of Future Minimum Payments Under Operating Lease (Details) $ in Thousands	Apr. 30, 2020USD ($)
Leases [Abstract]
2020	$ 1,233
2021	1,318
2022	1,369
2023	1,395
2024	1,419
Thereafter	1,564
Total	$ 8,298

Stockholders' Equity (Details N

Stockholders' Equity (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	Mar. 29, 2019	Jan. 31, 2020	Apr. 30, 2019	Apr. 30, 2020	Apr. 30, 2020	Oct. 31, 2019	Feb. 21, 2019
Common stock, shares authorized				170,000,000	170,000,000	170,000,000	95,000,000
Reverse stock split, description	1 for 15 reverse stock split.
Number of warrants to purchase common stock				5,398,226	5,398,226	432,142
Warrant exercise price per share				$ 0.372	$ 0.372	$ 0.372
Net proceeds from offering		$ 9,600		$ 11,600	$ 303,800
Public Offering [Member]
Number of common stock shares sold		10,000,000	2,500,000
Share price per share		$ 1.05	$ 4
Proceeds from sale of common shares		$ 10,500	$ 9,000
Private Placement [Member]
Number of warrants to purchase common stock		5,000,000
Warrant exercise price per share		$ 1.25

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Stockholders Equity (Details) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Apr. 30, 2020	Jan. 31, 2020	Apr. 30, 2019	Jan. 31, 2019	Apr. 30, 2020	Apr. 30, 2019
Beginning balance	$ 41,548	$ 39,531	$ 37,500	$ 24,051	$ 39,531	$ 24,051
Stock based compensation	210	242		622
Stock based compensation, shares			479
Tax withholdings paid on equity awards			$ (3)	(11)
Tax shares sold to pay for tax withholdings on equity awards			$ 3	11
Issuance of shares to employees under ESPP Plan	2	2		9
Issuance of shares to employees under ESPP Plan, shares			7
ESPP Expense			$ 1	1
Advaxis public offerings		9,628	8,982
Advaxis public offerings, shares					32,500
Warrant exercises		2	68
Warrant liability reclassified into equity			53		$ 2	53
Shares issued in settlement of warrants			5,463
Net Income	(6,323)	(7,857)	(9,383)	12,817	(14,180)	3,434
Ending balance	35,437	41,548	43,170	37,500	35,437	43,170
Preferred Stock [Member]
Beginning balance
Beginning balance, shares
Stock based compensation
Stock based compensation, shares
Tax withholdings paid on equity awards
Tax shares sold to pay for tax withholdings on equity awards
Issuance of shares to employees under ESPP Plan
Issuance of shares to employees under ESPP Plan, shares
ESPP Expense
Advaxis public offerings
Advaxis public offerings, shares
Warrant exercises
Warrant exercises, shares
Warrant liability reclassified into equity
Shares issued in settlement of warrants
Shares issued in settlement of warrants, shares
Net Income
Ending balance
Ending balance, shares
Common Stock [Member]
Beginning balance	$ 60	$ 50	$ 5	$ 5	$ 50	$ 5
Beginning balance, shares	60,236,599	50,201,671	4,646,007	4,634,189	50,201,671	4,634,189
Stock based compensation
Stock based compensation, shares	5,651	2,957	693	9,811
Tax withholdings paid on equity awards
Tax shares sold to pay for tax withholdings on equity awards
Issuance of shares to employees under ESPP Plan
Issuance of shares to employees under ESPP Plan, shares	2,694	5,555	1,505	2,007
ESPP Expense
Advaxis public offerings		$ 10	$ 2
Advaxis public offerings, shares		10,000,000	2,500,000
Warrant exercises
Warrant exercises, shares	7,500	26,416	15,300
Warrant liability reclassified into equity
Shares issued in settlement of warrants			$ 1
Shares issued in settlement of warrants, shares			856,865
Net Income
Ending balance	$ 60	$ 60	$ 8	$ 5	$ 60	$ 8
Ending balance, shares	60,252,444	60,236,599	8,020,370	4,646,007	60,252,444	8,020,370
Additional Paid-In Capital [Member]
Beginning balance	$ 433,614	$ 423,750	$ 392,335	$ 391,703	$ 423,750	$ 391,703
Stock based compensation	210	242		622
Stock based compensation, shares			479
Tax withholdings paid on equity awards			$ (3)	(11)
Tax shares sold to pay for tax withholdings on equity awards			$ 3	11
Issuance of shares to employees under ESPP Plan	2	2		9
Issuance of shares to employees under ESPP Plan, shares			7
ESPP Expense			$ 1	1
Advaxis public offerings		9,618	8,980
Warrant exercises		2	68
Warrant liability reclassified into equity			53
Shares issued in settlement of warrants			5,462
Net Income
Ending balance	433,826	433,614	407,385	392,335	433,826	407,385
Accumulated Deficit [Member]
Beginning balance	(392,126)	(384,269)	$ (354,840)	(367,657)	(384,269)	(367,657)
Stock based compensation
Stock based compensation, shares
Tax withholdings paid on equity awards
Tax shares sold to pay for tax withholdings on equity awards
Issuance of shares to employees under ESPP Plan
Issuance of shares to employees under ESPP Plan, shares
ESPP Expense
Advaxis public offerings
Warrant exercises
Warrant liability reclassified into equity
Shares issued in settlement of warrants
Net Income	(6,323)	(7,857)	(9,383)	12,817
Ending balance	$ (398,449)	$ (392,126)	$ (364,223)	$ (354,840)	$ (398,449)	$ (364,223)

Fair Value - Schedule of Fair V

Fair Value - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - USD ($) $ in Thousands	Apr. 30, 2020	Oct. 31, 2019
Common stock warrant liability, warrants exercisable	$ 40	$ 19
Fair Value, Inputs, Level 1 [Member]
Common stock warrant liability, warrants exercisable
Fair Value, Inputs, Level 2 [Member]
Common stock warrant liability, warrants exercisable
Fair Value, Inputs, Level 3 [Member]
Common stock warrant liability, warrants exercisable	$ 40	$ 19

Fair Value - Schedule of Fair_2

Fair Value - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) (Parenthetical) - $ / shares	Apr. 30, 2020	Oct. 31, 2019
Fair Value Disclosures [Abstract]
Warrant exercise price per share	$ 0.372	$ 0.372

Fair Value - Schedule of Change

Fair Value - Schedule of Changes in Fair Value of Warrant Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended
	Apr. 30, 2020	Jan. 31, 2020	Apr. 30, 2019	Apr. 30, 2020
Beginning balance		$ 19		$ 19
Warrant exercises		2	$ 68
Ending Balance	40			40
Warrant Liability [Member]
Beginning balance		$ 19		19
Warrant exercises				(2)
Change in fair value				23
Ending Balance	$ 40			$ 40

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	May 08, 2020	May 04, 2020	Jan. 31, 2020	Apr. 30, 2020	Apr. 30, 2020	Oct. 31, 2019	Feb. 21, 2019
Common stock, shares authorized				170,000,000	170,000,000	170,000,000	95,000,000
Proceeds from aggregate offering price			$ 9,600,000	$ 11,600,000	$ 303,800,000
Subsequent Event [Member] | Directors, Officers and Employees [Member]
Number of option granted		450,000
Option price		$ 0.66
Vesting percentage		100.00%
Vesting period, description		The stock options vest one-third after the one year anniversary, one-third after the two year anniversary and one-third after the three year anniversary.
Subsequent Event [Member] | 2015 Incentive Plan [Member] | Minimum [Member]
Common stock, shares authorized		877,744
Subsequent Event [Member] | 2015 Incentive Plan [Member] | Maximum [Member]
Common stock, shares authorized		6,000,000
Subsequent Event [Member] | Equity Offering Program [Member] | Sales Agreement [Member] | Alliance Global Partners [Member]
Number of common stock shares sold	1,353,237
Proceeds from sale of common shares	$ 1,033,000
Share price per share	$ 0.79
Proceeds from commission	$ 34,000
Subsequent Event [Member] | Equity Offering Program [Member] | Maximum [Member] | Sales Agreement [Member] | Alliance Global Partners [Member]
Proceeds from aggregate offering price	40,000,000
Subsequent Event [Member] | At-the-Market Program [Member] | Sales Agreement [Member] | Alliance Global Partners [Member]
Proceeds from sale of common shares	$ 1,067,000